Previous close | 0.6100 |
Open | 0.5900 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.5900 - 0.5900 |
52-week range | 0.5600 - 1.2700 |
Volume | |
Avg. volume | 199 |
Market cap | 14.997M |
Beta (5Y monthly) | 1.35 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8100 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 20.00 |
Traws Pharma ( NASDAQ:TRAW ) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90...
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”). On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accep
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential best-in-class/class leading assets: viroksavir, a cap-dependent endonuclease inhibitor for influenza; travaltrelvir, a protease inhibitor for COVID19; and narazaciclib, a next generation CDK4/6 inhibitor for low grade endometriod endometrial cancer (LGEEC)Multiple near-term catalysts, for viroksavir and travaltrevir